Literature DB >> 688698

Effect of corticosteroids on committed lymphocytes.

S J Ramer, D T Yu.   

Abstract

Human peripheral blood lymphocytes were cultured for 48 hr with concanavalin A. The amount of [3H]thymidine incorporated during the last 4 hr of culture, as well as the percentage of rosettes of activated lymphocytes generated, were assayed at the 48th hr. Adding 0.1 M alpha-methyl-D-mannoside (MAM) at progressively later times after the initiation of culture caused progressively less suppression because of the commitment phenomenon. This suppression was not exceeded by the addition of 10(-4) M preparations of corticosteroids and was statistically the same as that induced by a combination of both corticosteroids and MAM. The addition of PGE2 alone and in combination with methylprednisolone also failed to affect [3H]thymidine incorporation by committed lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 688698      PMCID: PMC1541313     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  The kinetics of suppression of proliferation of oxidized murine lymphoid cells by sodium borohydride reduction.

Authors:  L T Furcht; S R Gentry
Journal:  Cell Immunol       Date:  1976-03-15       Impact factor: 4.868

2.  Human lymphocyte subpopulations: suspension-sheep red-blood-cell rosettes.

Authors:  D T Yu
Journal:  Clin Immunol Immunopathol       Date:  1977-09

3.  Inhibition of human leukocyte mitosis by prednisolone in vitro.

Authors:  P C NOWELL
Journal:  Cancer Res       Date:  1961-12       Impact factor: 12.701

4.  Effect of corticosteroids on the response of lymphocytes to stimulation by galactose oxidase-modified lymphocytes.

Authors:  D T Yu; S J Ramer; A Kacena
Journal:  Immunology       Date:  1977-08       Impact factor: 7.397

5.  Requirement of the macrophage or its products for the transformation of cortisol-resistant human lymphocytes by phytohemagglutinin.

Authors:  D H Heilman; M R Gambrill
Journal:  Immunol Commun       Date:  1974

6.  Cellular immunity after intravenous administration of methylprednisolone.

Authors:  M L Webel; R E Ritts; H F Taswell; J V Danadio; J E Woods
Journal:  J Lab Clin Med       Date:  1974-03

7.  Characteristics of a cytotoxin ("lymphotoxin") produced by stimulation of human lymphoid tissue.

Authors:  J B Peter; J A Stratton; K E Stempel; D Yu; C Cardin
Journal:  J Immunol       Date:  1973-09       Impact factor: 5.422

8.  Effect of hydrocortisone on response of human lymphocytes to galactose oxidase stimulation.

Authors:  D Tak Yan Yu
Journal:  Int Arch Allergy Appl Immunol       Date:  1976

9.  Synergistic effect of cortisol and prostaglandin E2 on the PHA response. Relation to immunosuppression induced by trauma.

Authors:  M C Berenbaum; W A Cope; R V Bundick
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

10.  Enhanced effects of prostaglandin E1 and dibutyryl cyclic AMP upon human lymphocytes in the presence of cortisol.

Authors:  J Mendelsohn; M M Multer; R F Boone
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

View more
  4 in total

1.  Behaviour of human immunoregulatory cells in culture. I. Variables requiring consideration for clinical studies.

Authors:  J M Dwyer; C Johnson; M Desaules
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

2.  Effects of therapeutic drugs on lymphocyte transformation.

Authors:  W R Williams; L A Davidson
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

3.  Cell cycle-specific effects of glucocorticoids on phytohaemagglutinin-stimulated lymphocytes.

Authors:  J C Sloman; P A Bell
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

4.  Immunosuppression with glucocorticoids--a possible immunological explanation for interpatient variation in sensitivity: discussion paper.

Authors:  J S Beck; M C Browning
Journal:  J R Soc Med       Date:  1983-06       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.